Helping investors discover, understand, and stay up-to-date on investment opportunities within the Psychedelic industry.

Markets

Performance of psychedelic public companies this past week.

Company News

‍Tryp Therapeutics ($TRYP | $TRYPF) announced that the first patient has been dosed in their Phase II clinical trial. The study is focused on the safety and preliminary efficacy of psilocybin-assisted therapy among patients with binge eating disorder. Press Release

Optimi Health ($OPTI | $OPTHF) opened Canada's largest GMP-grade licensed psilocybin cultivation facility. Optimi’s facility will be focused on the production of natural GMP psilocybin for use in clinical trials and individuals granted access by Health Canada. Press Release

Field Trip Health ($FTRP) announced their intentions to separate the Field Trip Discovery and Field Trip Health division into two independent public companies. The transaction will create two distinct emerging leaders in the psychedelics industry, one providing personalized care and the other developing next generation psychedelic therapies. Press Release

Wellbeing Digital Sciences (($MEDI | $KONEF) announced that their subsidiary, IRP Health, has been approved as part of the Chronic Pain Centre of Excellence for Canadian veterans. Additionally, IRP Health’s clinic in Ottawa has been approved by Veterans Affair Canada for their multidisciplinary Reactivation-branded therapy program. Press Release

Filament Health ($FH | $FLHLF) has been issued a fourth patent for the extraction and standardization of natural psilocybin and associated psychedelic compounds. Filament's latest patent describes essential technology for transforming variable psychedelic raw materials into pharmaceutical-grade, standardized drug candidates. Press Release

PsyBio Therapeutics ($PSYB | $PSYBF) submitted an application to convert existing provisional patents to full patents. The submission covers major markets including North America, Europe, Asia-Pacific, and Africa. Press Release

PharmaTher Holdings ($PHRM | $PHRRF) provided operational updates. Highlights included a research collaboration with Revive Therapeutics, orphan drug designation for ketamine to treat status epilepticus, and a patent for a formulation of FDA-approved ketamine and betaine anhydrous KETABET. Press Release

Albert Labs International ($ABRT) appointed Professor Robert Britton, a Natural Product Chemist, and renowned toxicologist and pharmacologist, Dr. Dinis-Oliveira, to their Scientific Advisory Board. Press Release

Media‍

Psychedelic Finance:Interview With Dr. Albert Garcia-Romeu of Johns Hopkins University School of Medicine‍

Denver Post: Denver Is Leading The Way For Legal Psilocybin‍

Seattle Times: Brainstorming The Future of Psychedelic Research‍

Drug Science: Psilocybin Therapy for Treatment-Resistant Depression

Be the first to see new company features, exclusive interviews and breaking news. Subscribe now.

‍